GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
Gastrointestinal
Latest in
Gastrointestinal
EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
The latest approval is based on findings from three randomised, multicentre, Phase III trials of Rinvoq.
Takeda announces 11.6% reported revenue growth in FY2021
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
Will Dupixent change the treatment paradigm for EoE?
Key opinion leaders expect Dupixent to target patients who do not respond to current oeosinophilic oesophagitis (EoE) therapies.
By
Kallyope raises $236m to develop gut-brain axis treatment programmes
The proceeds will be used to advance the development of its compounds currently in clinical trials.
Pfizer signs agreement to acquire Arena Pharmaceuticals for $6.7bn
Arena’s portfolio includes several candidates in gastroenterology, dermatology and cardiology.
Asia-Pacific has seen the largest growth in gastrointestinal related trials over the past decade
We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.
By
Evolving eosinophilic esophagitis market in the United States
GlobalData anticipates a dynamic eosinophilic esophagitis market with a range of treatment options in the coming years.
By